Literature DB >> 12126587

B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.

William Stohl1.   

Abstract

The size of the known members of the tumor necrosis factor ligand and receptor superfamilies has burgeoned in the past few years. Among the novel tumor necrosis factor ligand and receptor superfamily members recently described is B lymphocyte stimulator (BLyS; Human Genome Sciences, Rockville, MD) protein. By virtue of its ability to promote B-cell survival, expansion, and differentiation, it likely plays an important contributory role in systemic lupus erythematosus pathogenesis and propagation. In addition, it may play a similar role in other systemic immune-based rheumatic diseases, and becomes a legitimate candidate target for antagonist biologic agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12126587     DOI: 10.1007/s11926-002-0044-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  48 in total

1.  B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Authors:  S Xu; K P Lam
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily.

Authors:  G U von Bülow; R J Bram
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

3.  TALL-1 is a novel member of the TNF family that is down-regulated by mitogens.

Authors:  H B Shu; W H Hu; H Johnson
Journal:  J Leukoc Biol       Date:  1999-05       Impact factor: 4.962

4.  Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints.

Authors:  M G Ridley; G Kingsley; C Pitzalis; G S Panayi
Journal:  Br J Rheumatol       Date:  1990-04

5.  Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase.

Authors:  A Mukhopadhyay; J Ni; Y Zhai; G L Yu; B B Aggarwal
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

6.  Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood.

Authors:  E Hagiwara; M F Gourley; S Lee; D K Klinman
Journal:  Arthritis Rheum       Date:  1996-03

7.  TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation.

Authors:  X Z Xia; J Treanor; G Senaldi; S D Khare; T Boone; M Kelley; L E Theill; A Colombero; I Solovyev; F Lee; S McCabe; R Elliott; K Miner; N Hawkins; J Guo; M Stolina; G Yu; J Wang; J Delaney; S Y Meng; W J Boyle; H Hsu
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

8.  A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth.

Authors:  P Rennert; P Schneider; T G Cachero; J Thompson; L Trabach; S Hertig; N Holler; F Qian; C Mullen; K Strauch; J L Browning; C Ambrose; J Tschopp
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

9.  BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.

Authors:  P Schneider; F MacKay; V Steiner; K Hofmann; J L Bodmer; N Holler; C Ambrose; P Lawton; S Bixler; H Acha-Orbea; D Valmori; P Romero; C Werner-Favre; R H Zubler; J L Browning; J Tschopp
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

10.  APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth.

Authors:  M Hahne; T Kataoka; M Schröter; K Hofmann; M Irmler; J L Bodmer; P Schneider; T Bornand; N Holler; L E French; B Sordat; D Rimoldi; J Tschopp
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

View more
  10 in total

Review 1.  Cutting-edge issues in celiac disease and in gluten intolerance.

Authors:  N Bizzaro; R Tozzoli; D Villalta; M Fabris; E Tonutti
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

2.  Is individualized medicine on the horizon for lupus?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

3.  What was wrong and might now go right with clinical trials for lupus?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

4.  Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis.

Authors:  M Schaller; W Stohl; S M Tan; V M Benoit; D M Hilbert; H J Ditzel
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

Review 5.  B cells in HIV infection and disease.

Authors:  Susan Moir; Anthony S Fauci
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

Review 6.  The BLyS family: toward a molecular understanding of B cell homeostasis.

Authors:  John F Treml; Yi Hao; Jason E Stadanlick; Michael P Cancro
Journal:  Cell Biochem Biophys       Date:  2008-11-26       Impact factor: 2.194

7.  Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy.

Authors:  Qiming Wang; Jeremy J Racine; Jeremy J Ratiu; Shu Wang; Rachel Ettinger; Clive Wasserfall; Mark A Atkinson; David V Serreze
Journal:  J Immunol       Date:  2017-10-20       Impact factor: 5.422

8.  Ex vivo characterization of Breg cells in patients with chronic Chagas disease.

Authors:  Magalí C Girard; Gonzalo R Acevedo; Micaela S Ossowski; Marisa Fernández; Yolanda Hernández; Raúl Chadi; Karina A Gómez
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

9.  Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice.

Authors:  Madelyn R Schmidt; Michael C Appel; Lisa J Giassi; Dale L Greiner; Leonard D Shultz; Robert T Woodland
Journal:  PLoS One       Date:  2008-09-11       Impact factor: 3.240

10.  CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells.

Authors:  Eliana Mariño; Jeanette Villanueva; Stacey Walters; David Liuwantara; Fabienne Mackay; Shane T Grey
Journal:  Diabetes       Date:  2009-03-31       Impact factor: 9.461

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.